The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This test analyses samples in VTM directly without the need for RNA extraction step
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Effectiveness of Covaxin against the Omicron variant is currently being studied
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Subscribe To Our Newsletter & Stay Updated
